Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Inclusion Criteria: * Ductal carcinoma in situ (DCIS) or Stage I-III, primary invasive carcinoma of the breast * Primary surgical treatment is planned to be a mastectomy or lumpectomy. Sentinel lymph node (LN) biopsy or axillary LN dissection (ALND) is planned as part of the subject's therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Adequate renal function * Lab values (hematology and chemistry) within institution's normal laboratory limits * Willing to remain on-site for approximately 24 hours after administration of AVB-620 or, if required, stay overnight after the surgical procedure * If the subject received neoadjuvant therapy, residual tumor is present (to be determined by the primary surgeon) * If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits * Subject has the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Recurrent ipsilateral breast cancer * Prior neoadjuvant chemotherapy or biologic therapy for current clinically or biopsy-proven node positive breast cancer within 4 weeks before the planned surgery. * Open surgery in the ipsilateral breast within 1 year of AVB-620 administration * History of radiation therapy to ipsilateral breast * Abnormal cardiac rhythm not controlled with medication, history of stroke, coronary events, and/or heart failure within 1 year of AVB-620 administration * Diagnosis of autoimmune disorders * History of drug-related anaphylactic reactions or allergic reactions; subjects with an active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids will be excluded * History of renal disease or current evidence of renal disease * Current diagnosis of any other active or clinically significant non-breast cancer * Systemic investigational drug of any kind within 6 weeks of AVB-620 administration * Pregnant or breast feeding